Castleview Partners’s Insmed INSM Stock Holding History

Castleview Partners’s Portfolio INSM Stock Details INSM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-15	Closed	-$299	–	689
2022 Q4	$299	Buy	+15	New	+$290	﹤0.01%	603

Other funds holding INSM

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

PAMS

Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return

William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return

Castleview Partners's INSM Position: Q1 2023 in Review

Castleview Partners sold out of Insmed (INSM) in Q1 2023, closing a stake of 15 shares — an estimated $299 sold.

Castleview Partners first reported a position in INSM in Q4 2022 and held it in 1 quarter. The position peaked at $299 in Q4 2022. 230 funds tracked by Wall St. Rank hold INSM as of Q1 2023.

Castleview Partners reported no remaining Insmed position as of Q1 2023 after selling out during the quarter.
Castleview Partners sold 15 Insmed shares in Q1 2023, an estimated $299.
Castleview Partners first reported a position in Insmed in Q4 2022 and held it in 1 quarter.
Castleview Partners's Insmed position peaked at $299 in Q4 2022.
230 funds tracked by Wall St. Rank held Insmed as of Q1 2023.

Based on Castleview Partners's 13F filing for Q1 2023, filed 16 May 2023.